View Older Stories View More Recent Stories

Aug 29, 2023 08:45AM Evolus to Participate in September Conferences
Aug 23, 2023 06:53PM Evolus Announces Inducement Grants for New Chief Marketing Officer
Aug 21, 2023 08:45AM Evolus (EOLS) Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
Aug 21, 2023 08:45AM Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
Aug 8, 2023 08:46AM Evolus (EOLS) Unveils New Branding for Jeuveau
Aug 8, 2023 08:45AM Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
Aug 2, 2023 04:05PM Evolus Reports Second Quarter 2023 Results and Provides Business Update
Jul 27, 2023 08:45AM Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
Jul 26, 2023 08:45AM Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
Jul 19, 2023 08:45AM Evolus to Report Second Quarter 2023 Results and Provide Business Update
Jun 29, 2023 09:00AM Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
Jun 22, 2023 08:46AM Evolus (EOLS) Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau
Jun 22, 2023 08:45AM Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
Jun 8, 2023 04:05PM Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
May 9, 2023 04:01PM Evolus (EOLS) Announces Expansion into U.S. Dermal Filler Market with Evolysse
May 9, 2023 04:01PM Evolus Reports First Quarter 2023 Results and Provides Business Update
May 9, 2023 04:01PM Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
May 5, 2023 01:37PM Evolus to Report First Quarter 2023 Results and Provide Business Update
Mar 8, 2023 04:05PM Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Feb 28, 2023 08:45AM Evolus to Participate in the Barclays Global Healthcare Conference
Feb 27, 2023 08:45AM Evolus (EOLS) Announces Nuceiva Launch in Germany and Austria
Feb 27, 2023 08:45AM Evolus Initiates Nuceiva® Launch in Germany and Austria
Feb 22, 2023 08:45AM Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
Feb 10, 2023 11:07AM Evolus (EOLS) Says It is Not Affected by Recent Korean Court Ruling
Feb 10, 2023 11:07AM Evolus Not Affected by Recent Korean Court Ruling
Jan 31, 2023 08:45AM Evolus to Participate in the SVB Securities Global Biopharma Conference
Jan 29, 2023 06:34PM Evolus (EOLS) Reports "Extra-Strength" Formulation of Jeuveau Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data
Jan 28, 2023 08:00AM "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
Jan 23, 2023 09:01AM Evolus (EOLS) Receives Regulatory Approval for Nuceiva® in Australia
Jan 23, 2023 09:00AM Evolus Receives Regulatory Approval for Nuceiva® in Australia
Jan 23, 2023 08:00AM Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
Jan 18, 2023 08:45AM Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
Dec 8, 2022 08:45AM Evolus Extends Term of Credit Facility with Pharmakon Advisors
Nov 8, 2022 04:05PM Evolus Reports Third Quarter 2022 Results and Provides Business Update
Nov 2, 2022 08:45AM Evolus to Participate in November Conferences
Oct 25, 2022 08:45AM Evolus to Report Third Quarter 2022 Results and Provide Business Update
Sep 21, 2022 08:47AM Evolus (EOLS) Concludes Certain Royalty Payments
Sep 21, 2022 08:45AM Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
Sep 6, 2022 04:05PM Evolus Announces Inducement Grants for New Chief Financial Officer
Aug 30, 2022 08:16AM Evolus (EOLS) Appoints Sandra Beaver as CFO
Aug 30, 2022 08:15AM Evolus Appoints Sandra Beaver as Chief Financial Officer
Aug 29, 2022 05:45AM Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug 24, 2022 08:15AM Evolus (EOLS) Reports Publication of Post Hoc Analysis Evaluating Efficacy of Jeuveau vs BOTOX
Aug 24, 2022 08:14AM Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®
Aug 2, 2022 08:05AM Evolus Reports Second Quarter 2022 Results and Provides Business Update
Jul 19, 2022 08:45AM Evolus to Report Second Quarter 2022 Results and Provide Business Update
Jul 19, 2022 08:37AM Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
Jul 12, 2022 08:47AM Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
Jun 2, 2022 08:55AM Evolus (EOLS) Reports Publication of Post Hoc Analysis Showing Jeuveau Highly Effective for Millennials
Jun 2, 2022 08:54AM Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
View More Recent Stories View Older Stories